cypd

CypD-IN-29 is a non-peptidic inhibitor of cyclophilin D as a neuroprotective agent in Aβ-induced mitochondrial dysfunction.

1. Ganoderic acid D is one of the major components in Ganoderma triterpenes. 2. Ganoderic acid D treatment for 48h inhibits the proliferation of HeLa human cervical carcinoma cells with an IC(5) value of 17.3 +/- .3 microM.

MDL-27088 is an angiotensin-covering enzyme inhibitor.

CypD-IN-3, a potent and subtype-selective cyclophilin D (CypD) inhibitor, exhibits a high affinity for CypD with an IC50 value of 0.01 μM. It is applicable in the research of various conditions, such as oxidative stress, neurodegenerative disorders, liver diseases, aging, autophagy, and diabetes [1].

CypD-IN-4 is a potent, subtype-selective cyclophilin D (CypD) inhibitor exhibiting a high affinity for CypD with an IC50 value of 0.057 μM. This compound is utilized in the research of various diseases, such as oxidative stress, neurodegenerative disorders, liver diseases, aging, autophagy, and diabetes [1].

CypD inhibitor C-9 is a CypD inhibitor, it attenuates mitochondrial and cellular perturbation insulted by Aß and calcium stress.

C105SR is a cyclophilin D (CypD) inhibitor targeting peptidyl-prolyl cis-trans isomerase (PPIase). It has an IC50 value of 5 nM for inhibiting mitochondrial permeability transition pore (mPTP) opening. C105SR reduces apoptosis in hepatocytes induced by hypoxia-reoxygenation and boosts calcium retention capacity (CRC). It demonstrates hepatoprotective effects in a mouse model of ischemia-reperfusion injury (IRI).

CypD-IN-1, a potent and subtype-selective inhibitor targeting cyclophilin E (CypE), demonstrates high affinity with IC50 and Ki values of 0.013 μM and 0.072 μM, respectively. This compound is valuable for research into various conditions, including oxidative stress, neurodegenerative disorders, liver diseases, aging, autophagy, and diabetes [1].